Summary. The value of plasma insulin, human Cpeptide and proinsulin estimation in the diagnosis of 15 insulinomas has been investigated. Measurement of plasma proinsulin in an overnight fasting sample diagnosed all the insulinomas studied, irrespective of the plasma glucose. Patients with insulinomas had plasma proinsulin in the range 0.04-4.2 pmol/1 and normal values were less than 0.01 pmol/ml. If hypoglycaemia was present, an inappropriately raised plasma immunoreactive insulin (including proinsulin) was diagnostic, but this assay was of little assistance if the plasma glucose was normal. Hypoglycaemia was induced with fish insulin in twelve patients with insulinomas and eight normal subjects. Using an antiserum which did not detect fish insulin, but cross-reacted with human proinsulin, the endogenous immunoreactive insulin was suppressed in the normal subjects, but all insulinoma patients had impaired suppression. Assay of plasma human Cpeptide, or of the combined immunoreactive C-peptide and proinsulin, discriminated less well and did not clearly diagnose three insulinomas which secreted proinsulin rather than insulin and C-peptide. Plasma human proinsulin values during induced hypoglycaemia gave excellent discrimination and should detect insulinomas irrespective of their degree of histological differentiation. The assay of plasma hurnan proinsulin allows a suppression test to be performed with hypoglycaemia induced by any type of insulin. A raised plasma proinsulin in proportion to C-peptide suggests an undifferentiated insulinoma, which may be more likely to be malignant.
proinsulin, C-peptide, insulin.
Stimulation tests for insulinomas are unreliable as they give both false positive and negative results [1, 2] . Insulinomas can be more precisely diagnosed by suppression tests, in which one monitors the homoeostatic control of secretion in response to hypoglycaemia [3] . Normal subjects have marked suppression of insulin secretion in response to a decrease in plasma glucose, whereas patients with insulinomas have impaired suppression [4] . Insulinomas characteristically present with fasting hypoglycaemia, and demonstration of inappropriately raised plasma insulin levels in relation to a low plasma glucose is sufficient for the diagnosis [4] .
The plasma human insulin response to fish insulin-induced hypoglycaemia provides a dynamic suppression test, which enables diagnosis in those patients with insulinomas who have a normal overnight fasting plasma glucose concentration [4] . Fish insulin is however, not readily available. An alternative means of assessing endogenous beta cell secretion is the assay of plasma human C-peptide following administration of pork or beef insulin [5, 6] . Insulinomas are frequently undifferentiated [7] and secrete proinsulin rather than insulin and C-peptide [8, 9] . We have therefore studied the plasma insulin, C-peptide and proinsulin responses to induced hypoglycaemia in normal subjects, and in patients with insulinomas, to determine the relative diagnostic value of these assays.
Me~o~
Fourteen patients who had suspected hypoglycaemic episodes were given a fish insulin suppression test for diagnostic purposes. After an overnight fast a teflon intravenous catheter was inserted into a forearm vein using local anaesthesia. After two lack of suppression of plasma immunoreactive insufin during induced hypoglycaemia suggested insulinomas, which were later confirmed at operation when one was found to be malignant. These patients (8 female, and 4 male) were aged 7 to 72 years (mean 51 years) and were on average 11% over ideal weight (range 2-33%). The plasma insulin responses have been previously reported [4] . One of the other patients had neurofibromatosis and normal plasma insulin suppression, and had fasting hypoglycaemia of uncertain cause. The other later admitted to self-administration of insulin. Eight normal subjects (4 female, 4 male, aged 21--48, all less than 15% over ideal weight) gave informed consent for a fish insulin test. Plasma samples were taken, after an overnight fast, from three other patients with insulinomas, one of which was malignant. No patients or normal subjects were receiving drug therapy when studied.
Plasma human C-peptide was assayed in the supernatant after removal of proinsulin and insulin with insulin antibodies bound to sepharose particles suspension (100~tl with binding capacity for 0.1 U/ml insulin) was added to 1 ml of plasma and shaken overnight at 4 ~ An aliquot of the supernatant (100 ~tl) was used for C-peptide determination. For proinsulin assay, human proinsulin standards (kindly provided by Dr. A. Rubenstein) were treated identically. The precipitate was washed twice with 2 ml of phosphate buffer, 0.04 mol/1, pH 7.4 containing human albumin (60g/l), thiomersal (0.2 g/l) and sodium chloride (6 g/l). The antiserum (200 pl of 1/600 solution of Ml181) was added to the precipitate and shaken overnight at 4 ~ C. An aliquot of the supernatant (200 btl) was transferred to tubes containing 100~tl of ~:5I Tyr-C-peptide (0.2 pmol/ml) and after 24 hours incubation, free and bound C-peptide separated. A proinsulin standard curve is shown in Figure 1 .
Plasma human insulin levels were measured with charcoal phase separation . [l l], using an antiserum which has little cross-reaction with fish insulin (GP5, Dr. Lowy) and Novo M.C. human insulin standard (kindly provided by Dr. J. Schlichtkrull). Assuming the plasma insulin was one sixth the molar concentration of C-peptide [12] , the results of plasma Cpeptide, insulin and proinsulin of the patients who secreted predominantly proinsulin (see Fig. 6 ) indicated that proinsulin reacted in this'assay with approximately 35% of the affinity of insulin.
The percent proinsulin in the plasma was calculated by dividing the plasma proinsulin by the sum of the individual proinsulin and C-peptide results, The combined immunoreactivity of C-peptide and proinsulin in the plasma was assessed with direct assay of the plasma with labelled C-peptide, antiserum M 1181 and the C-peptide standard. In this assay the proinsulin reacted with approximately 25% (molar concentrations) of the affinity of C-peptide for the antiserum. Plasma glucose was measured using a manual glucose oxidase kit (Boehringer).
Results

Basal Plasma Hormone Concentrations
The overnight, fasting plasma hormone concentration are shown in Figure 2 . Neither plasma insulin (normal subjects mean 0.044, insulinomas 0.120 pmol/ml) nor C-peptide assay (normal subjects mean 0.14, insulinomas 0.27 pmol/ml) alone gave diagnostic discrimination. The total immunoreactive C-peptide assay (normal subjects mean 0.24, insulinomas 0.33 pmol/ml) gave similar results to, and no more discrimination than, the C-peptide assay alone (normal subjects mean 0.21, insulinomas 0.29 pmol/ml). All the patients with insulinomas had raised, plasma proinsulin levels, (normal subjects < 0.01pmol/ml, insulinomas 0.042-4.2 pmol/ml). The proportion of proinsulin in the assayed plasma insulin was raised in the patients with insulinomas (proinsulin/C-peptide + proinsulin: normal subjects < 3%, insulinomas range, 11-43%, mean + SD 24 + 7%). One of the patients with a malignant insulinoma had a very high proportion of proinsulin (total immunoreactive insulin 2.13 pmol/ml, % proinsulin 43%), whereas the other had a proinsulin content which was similar to the benign insulinomas, (11% proinsulin, see Figure  2 ). If the usual expression of proinsulin/total immunoreactive insulin were used, normal subjects had < 18% proinsulin, whereas insulinomas ranged. from 17-223%, mean 82%.
Fish lnsulin Suppression Test
The plasma glucose fell in normal subjects from a fasting value of 4.0 _+ 0.2 to 2.6 + 0.7 mmol/1, and in the patients with insulinomas, from a fasting value of 2.6 + 0.8 mmol/1 (mean +_ ISD) to 1.4 _+ 0.6 mmol/1 at 90 minutes. The patients with insulinomas were tolerant of hypoglycaemia, and usually had neither signs nor symptoms of adrenaline secretion. Drowsiness was not noted in 6 patients until the plasma glucose became < 1 mmol/l. There was prompt return to normal faculties after glucose administration. We now know such marked hypoglycaemia is not diagnostically necessary. The rate. of fall of plasma C-peptide during the test in normal subjects (mean 0.19 to 0.09 pmol/ml at 90 minutes) was less than that of plasma insulin (mean 0.044 to 0.007 pmol/ml at 90 minutes). Assessment of the plasma immunoreactive insulin in relation to the hypoglycaemia gave excellent discrimination between patients with insulinomas and normal subjects (Fig. 3) . Although the C-peptide assay diagnosed the majority of the insulinomas, three had plasma C-peptide concentrations which were on the borderline of the normal range (Fig. 4) . The proinsulin assay gave excellent diagnostic discrimination (Fig. 5) . Insufficient plasma proinsulin was detected in the combined C-peptide and proinsulin assay to increase usefully the diagnostic discrimination of the C-peptide assay. The result from the three patients with insulinomas who were not easily diagnosed by C-peptide assay alone are shown in Figure 6 together with results from the patient with neurofibromatosis, whose hypoglycaemia was thought not to be due to an insulinoma. He had marked suppression of plasma immunoreactive insulin and proinsulin, but had plasma C-peptide levels which were just above the normal range, and could not be distinguished from the patients with insulinomas.
The patient with factitious hypoglycaemia due to self-administration of insulin had not formed insulin o gLg setuottTlnsu Im. opildod-E) ptre uilnsu!oa d emseld :gu!po H "O ""I pue aotuni "O '~I antibodies since there was no detectable binding of labelled insulin by her serum in the assay. Plasma insulin failed to suppress normally in response to fish insulin induced hypoglycaemia (remained at 0.025 mmol/1 whilst the plasma glucose fell from 3.8 to 1.8 mmol/1 over 80 minutes) but there was little detectable plasma human C-peptide (< 0.03pmol/ml) or human proinsulin (< 0.01 pmol/ml). She later admitted to injecting herself with insulin prior to the test and the exogenous insulin was detected in the insulin assay.
Discussion
These results show that suppression tests'using proinsulin or insulin assay discriminate between normal subjects and patients with insulinomas, but there is less diagnostic efficacy with C-peptide assay. Some insulinomas are histologically undifferentiated and secrete proinsulin rather than C-peptide and insulin [7, [13] [14] [15] . Assay of plasma C-peptide alone did not then adequately reflect beta cell secretion, and was not always abnormal in patients with insulinomas. In addition, the longer half life of C-peptide compared with insulin [16] means that suppression of beta cell secretion cannot be as easily monitored with C-peptide as with insulin assay. The insulin assay also detected proinsulin and gave excellent discrimination during a suppression test. However, if an antiserum which does not cross react with proinsulin were used, the insulin assay might be inadequate [17] , and would be no better than the C-peptide assay. Theoretically a combined C-peptide and proinsulin assay, like the combined insulin and proinsulin assay, might be useful during a suppression test. However, the greater amount of C-peptide in the plasma of normal subjects compared with proinsulin in the plasma of normal subjects or in the plasma of most patients with insulinomas, together with the lower affinity of our antiserum for proinsulin than C-peptide, means that the increased plasma content of proinsulin in insulinoma patients could not be sufficiently detected by this means. The total C-peptide immunoreactivity also failed to diagnose adequately the patient studied by Rayfield et al. [181.
Although a suppression test using C-peptide assay will diagnose most insulinomas, a proinsulin assay is necessary to detect undifferentiated adenomas. If one has a supply of fish insulin, then use of a human insulin assay which detects proinsulin provides an easy and satisfactory test for insulinomas, and indeed the longer half life of proinsulin compared with insulin enhances the apparent non-suppression of the insulinomas compared with normal subjects. Although this test appears to diagnose all insulinomas, it gave a false positive test in the patient who was surreptitiously administering pork or beef insulin at the time of the test. This was, however, proven by showing lack of human C-peptide and human proinsulin in her blood [19] . The ideal diagnostic suppression test is human proinsulin assay following hypoglycaemia induced by the easily available pork or beef insulin. The assay of proinsulin alone is, however, more complex than human insulin assay, although the separation using solid phase anti-insulin antibodies is considerably easier and more sensitive than gel filtration [20] .
The majority of patients with insulinomas have hypoglycaemia after an overnight fast, and an insulin assay which detects proinsulin detects the inappropriate beta cell secretion [4] . If the basal plasma glucose is normal, however, the total immunoreactive insulin concentration can also be normal. Nevertheless, all our patients had a raised plasma proinsulin, and a greater than normal proportion of their basal insulin as proinsulin. Thus assay of the proin-' sulin content of an overnight fasting blood sample will detect most insulinomas even though they have a normal fasting plasma glucose. A few patients with insulinomas have been reported to have normal plasma proinsulin content [9, 15] . In one study samples were taken after tolbutamide stimulation [8] , which is likely to decrease the proportion of proinsulin [21] . Occasionally some well differentiated insulinomas may have normal proinsulin secretion, and other diseases than insulinomas could have high plasma proinsulin concentrations, including familial proinsulinaemia [22] . Nevertheless, proinsulin assay in a basal sample is useful diagnostically, but demonstration of inappropriate beta cell secretion during hypoglycaemia must be the final arbiter of the diagnosis of an insulinoma. When investigating a patient suspected of an insulinoma, we take an overnight fasting blood sample. If rapid analysis reveals the plasma glucose < 2 mmol/1, sufficient hypoglycaemia is present for diagnostic purposes. If the concentration is higher, an insulin suppression test is performed until either that degree of hypoglycaemia is achieved or "hypoglycaemic symptoms" ensue.
A patient with a very high proportion of proinsulin probably has an undifferentiated turnout. These are more likely to be malignant, but our results confirm that malignancy of insulinomas is not directly correlated with the degree of differentiation [7, 9] . We have expressed the proinsulin proportion in terms of the sum of individual C-peptide and proinsulin assays. These are both accurate determinations, which are more reliable than direct plasma immunoreactive insulin assay which only partly detects proinsulin. The proinsulin content is usually then related to the total immunoreactive insulin. This expression has the disadvantage that if proinsulin is accurately measured in a proinsulin assay, the higher values which are obtained give results in some plasma samples of more than 100% of immunoreactive insulin being proinsulin. As C-peptide and proinsulin have similar half lives, and are not extracted by the liver, the result of our calculation probably reflects beta cell secretion more accurately than alternative expressions.
The patient with neurofibromatosis had normal suppression of plasma insulin and proinsulin, and is unlikely to have an insulinoma. He, however, had high C-peptide levels, which were out of proportion to the plasma insulin. Patients with neurofibromatosis have been reported to have increased plasma concentrations of nerve stimulatory activity [23] . Nerve growth factor has similarities to proinsulin [24] , and it is possible that the high levels of immunoreactive C-peptide of this patient were due to plasma nerve growth factor cross reacting in the Cpepfide assay. Raised plasma levels of NSILA-s, another growth factor, appear to cause hypoglycaemia in some patients with sarcoma [25] , and it is conceivable that high plasma levels of nerve growth factor might be implicated in the hypoglycaemia of our patient.
